Department of Oncology, Tom Baker Cancer Center, University of Calgary, 1331-29th Street North West, Calgary, Alberta, Canada.
Hematol Oncol Clin North Am. 2011 Aug;25(4):871-91. doi: 10.1016/j.hoc.2011.04.003.
The current treatment paradigm for metastatic renal cell carcinoma (RCC) includes agents that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways. Because these agents have revolutionized RCC over the past five years, new clinical and molecular predictive and prognostic tools are required. These are potentially important for therapy selection, patient counseling, and clinical trial stratification. This review examines clinical prognostic models and molecular biomarkers in RCC.
目前转移性肾细胞癌（RCC）的治疗模式包括针对血管内皮生长因子（VEGF）和哺乳动物雷帕霉素靶蛋白（mTOR）途径的药物。由于这些药物在过去五年中彻底改变了 RCC 的治疗，因此需要新的临床和分子预测和预后工具。这些对于治疗选择、患者咨询和临床试验分层具有潜在的重要意义。本综述探讨了 RCC 中的临床预后模型和分子生物标志物。
